Skip to main content

Table 2 IMP dosage protocol

From: The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure

SZC dose at start of visit

Serum potassium at visit

Dose change at end of visit

On 10 g daily

5.0–6.0 mmol/L

Continue 10 g daily

3.5–5.0 mmol/L

Change to 5 g daily

<  3.5 mmol/L

Stop

>  6.0 mmol/L

Stop and initiate rescue

On 5 g daily

>  5.0 mmol/L

Change to 10 g daily

3.5–5.0 mmol/L

Continue 5 g daily

<  3.5 mmol/L

Stop

On 0 g daily (i.e. temporary stop)

≤ 5.0 mmol/L

Continue with no IMP

>  5.0 mmol/L

Initiate 5 g daily

  1. Table 2—Dosage protocol for study visits based on serum potassium measurements. IMP may be restarted two weeks after discontinuation due to hypokalaemia depending on serum potassium result